IngredientesLos minerales traza—también llamados microminerales—son minerales esenciales que el cuerpo requiere en pequeñas cantidades (traza), pero desempeñan roles cruciales en el mantenimiento de la salud general, la función metabólica, la actividad enzimática y la integridad celular. A diferencia de los macrominerales como el calcio o el magnesio, los minerales traza se necesitan en cantidades mínimas pero son absolutamente vitales para procesos fisiológicos clave. Deben obtenerse a través de la dieta, la suplementación o fuentes de agua rica en minerales y fuentes de base edáfica.
Los minerales traza principales incluyen:
Beneficios para la salud y roles:
Fuentes:
Contexto Histórico y Moderno:
Aunque los minerales traza solo fueron identificados científicamente en el siglo XX, los sistemas de curación tradicionales valoraban los alimentos ricos en minerales, las arcillas, las cenizas y los manantiales minerales por sus efectos restauradores. En el Ayurveda, el uso de bhasmas (preparaciones de ceniza mineral purificada) refleja una comprensión temprana de su importancia.
Hoy en día, los minerales traza son reconocidos como fundamentales para la nutrición funcional, la salud endocrina, el equilibrio inmune y la longevidad celular. Las deficiencias—incluso las sutiles—pueden contribuir a la fatiga, la inmunidad deficiente, el deterioro cognitivo y la disfunción metabólica, lo que hace que la suplementación integral de minerales traza sea una parte clave de muchas estrategias de salud modernas.
Condiciones de salud que minerales traza puede ayudar a apoyar.
Clinical data suggest GLA supplementation may reduce acne lesions, partly by restoring the skin barrier and reducing inflammatory mediators. A 10-week trial found that 2,000 mg/day of borage oil (containing ~400 mg GLA) significantly decreased breakouts and acne-related lesions. GLA is metabolized to DGLA, a precursor of anti-inflammatory prostaglandin E1 that suppresses pro-inflammatory cytokines. Evidence remains preliminary and more rigorous trials are needed.
GLA reduces platelet aggregation and thromboxane B2 while increasing vascular prostacyclin—a profile that supports arterial health and reduces atherosclerotic risk factors. Clinical trials and observational data link GLA/DGLA levels to reduced cardiovascular events. Limited evidence suggests GLA may help prevent clogged arteries.
GLA is among the best-studied natural supplements for rheumatoid arthritis, with multiple randomized controlled trials demonstrating clinically relevant reductions in joint pain, swelling, and disease activity. A key 1996 double-blind RCT (n=56) found 2.8 g/day GLA over 6 months produced significantly greater improvement than placebo. Evidence is particularly strong compared to most herbal/supplement interventions for RA.
GLA has been investigated in clinical trials for ADHD, with the 1989 Arnold et al. placebo-controlled comparison to D-amphetamine being the earliest RCT. More recent omega-3/GLA combination trials show weak to modest evidence of benefit. GLA alone has generally not demonstrated robust efficacy in ADHD, but its role as an adjuvant anti-inflammatory agent in combination with omega-3s continues to be investigated.
GLA, an omega-6 PUFA found in borage, evening primrose, and black currant oils, is metabolized to dihomo-gamma-linolenic acid (DGLA), which produces anti-inflammatory eicosanoids. Clinical trials in rheumatoid arthritis have shown reductions in joint tenderness and swelling. It has been studied as adjunctive therapy in multiple autoimmune-mediated inflammatory conditions.
GLA supplementation significantly reduces platelet aggregation and serum thromboxane B2—a platelet activator—while increasing bleeding time and vascular prostacyclin, a profile consistent with reduced thrombotic risk. A 4-month clinical study in hyperlipidemic patients documented ~45% reduction in platelet aggregation with GLA.
GLA combined with EPA has lowered blood pressure in two clinical trials involving over 100 subjects. A 3-month GLA supplementation study in older subjects was associated with beneficial reduction in arterial hypertension. GLA is also theorized to reduce blood pressure via PGE1-mediated vasodilation, with supportive animal data showing dose-dependent BP reduction.
GLA's primary connection to blood sugar is through diabetic neuropathy: diabetics have an impaired ability to convert linoleic acid to GLA, and GLA supplementation corrects the downstream deficit in nerve membrane lipids. GLA itself does not directly lower blood glucose but addresses glucose-related nerve damage and metabolic dysregulation downstream of glycemic disruption.
A pilot RCT found that GLA combined with EPA and calcium significantly preserved and increased lumbar spine and femoral bone mineral density (BMD) in elderly women versus calcium alone over 18–36 months. Animal work shows GLA and EPA enhance calcium absorption and deposition in bone. Evidence is limited but encouraging.
Clinical evidence shows GLA supplementation reduces total cholesterol and LDL-cholesterol while raising HDL-cholesterol in hyperlipidemic patients. Studies show significant cholesterol improvements alongside triglyceride reductions. Effects appear dose-dependent and more pronounced with longer supplementation periods.
GLA exerts documented anti-inflammatory effects through conversion to DGLA and subsequent production of prostaglandin E1 (PGE1) and 15-OH-DGLA, which inhibit pro-inflammatory eicosanoids. Multiple clinical trials in inflammatory conditions (RA, atopic dermatitis, rosacea) confirm measurable reductions in inflammatory markers and symptom scores. It is considered one of the few omega-6 fatty acids with a predominantly anti-inflammatory metabolic profile.
Gamma-linolenic acid (GLA), the active component of evening primrose and borage oils, has been studied for atopic dermatitis based on the theory of impaired delta-6-desaturase activity in AD patients. Clinical trial results are mixed, with modest improvements in some studies but no significant benefit in others.
GLA is an omega-6 fatty acid and precursor to prostaglandin E1 (PGE1), a key molecule for tear production and lacrimal gland secretion. Multiple RCTs using GLA combined with EPA/DHA showed improved tear film lipid layer stability, reduced tear evaporation, and reduced DED inflammation. Sources include borage and evening primrose oil.
GLA is an omega-6 fatty acid from evening primrose, borage, and blackcurrant oils that restores skin barrier lipids impaired by delta-6-desaturase deficiency in dry/atopic skin. Clinical studies confirm GLA plasma levels correlate with dry skin improvement, and supplementation reduces TEWL and inflammatory barrier dysfunction. GLA converts to DGLA, producing anti-inflammatory prostaglandins that support skin hydration.
Gamma-linolenic acid (GLA) is the key active constituent in evening primrose oil and borage oil, mechanistically relevant to atopic eczema via the delta-6-desaturase deficiency hypothesis. Some RCTs show improvements in skin hydration and inflammation in atopic dermatitis, though results across trials are inconsistent and the Cochrane review found no consistent benefit.
GLA has demonstrated several cardioprotective properties in human trials including reduction in triglycerides, LDL-cholesterol, platelet aggregation, thromboxane B2, and blood pressure, alongside increases in HDL-cholesterol and prostacyclin production. These lipid and platelet effects collectively reduce cardiovascular risk markers.
GLA (via evening primrose oil) has been tested in multiple RCTs for menopausal hot flashes with some evidence of benefit. A randomized double-blind trial (n=56 menopausal women, BMJ 1994) found gamolenic acid from EPO significantly reduced daytime hot flush frequency. Subsequent trials and systematic review data support a modest but real effect on hot flush severity and frequency.
GLA-containing oils (evening primrose oil) have clinical evidence for relieving several menopausal symptoms including hot flashes, night sweats, and psychological symptoms. Multiple controlled trials support modest but statistically significant benefits. GLA's eicosanoid-modulating effects are hypothesized to underlie these benefits.
GLA influences prostaglandin metabolism through DGLA/PGE1, with PGE1 known to relax smooth muscle and oppose the uterine-contracting prostaglandins central to menstrual pain. A double-blind RCT found GLA supplementation significantly reduced PMS symptom severity in women with documented lower DGLA levels. EPO has a traditional and evidence-based history of use for menstrual symptoms.
GLA has been used for metabolic syndrome (Syndrome-X) based on its documented effects on multiple metabolic syndrome components: triglycerides, HDL-cholesterol, LDL-cholesterol, and blood pressure. Clinical reference sources list metabolic syndrome as a recognized indication for GLA, and its lipid and anti-inflammatory effects are mechanistically relevant.
GLA and its metabolites are required for normal neuronal membrane structure, nerve blood flow, and impulse conduction. Diabetics have impaired GLA synthesis and develop neuropathy partly due to GLA deficiency. Multiple controlled trials show GLA supplementation significantly improves neurophysiological parameters in diabetic neuropathy.
Gamma-linolenic acid (GLA) is an omega-6 fatty acid whose supplementation has been shown in multiple RCTs to benefit diabetic peripheral neuropathy by correcting a metabolic deficiency in GLA conversion seen in diabetic patients. A GLA Multicenter Trial Group RCT (n=111, 12 months) showed significant improvement across 16 neuropathy measures. A 2019 noninferiority RCT demonstrated GLA was comparable to alpha-lipoic acid for painful diabetic neuropathy.
GLA combined with EPA supplementation has been shown in a pilot RCT to preserve and modestly increase bone mineral density in elderly women, supporting a role in osteoporosis prevention. Animal data consistently show GLA enhances calcium absorption and deposition. Evidence is preliminary but mechanistically grounded.
Gamma-linolenic acid (GLA), an omega-6 fatty acid predominant in evening primrose oil and borage oil, has been studied as an active component for perimenopausal hot flash relief via prostaglandin pathway modulation. It is the key bioactive constituent underlying evening primrose oil's studied benefits during perimenopause.
GLA has been investigated for psoriasis both topically and orally, with some evidence supporting modest benefit through its anti-inflammatory eicosanoid-modulating properties. Clinical and mechanistic data suggest GLA may reduce inflammatory components of psoriatic skin, though a systematic review found EPO did not demonstrate effectiveness for psoriasis in controlled trials. Evidence is mixed.
GLA (gamma-linolenic acid), the bioactive in evening primrose and borage oils, is identified in a 2025 PMC systematic review as effective in atopic dermatitis-related itching and inflammatory skin rashes. It suppresses pro-inflammatory arachidonic acid-derived eicosanoid synthesis and has been studied in multiple skin-condition RCTs.
GLA, an omega-6 fatty acid found in evening primrose oil, was studied in a double-blind placebo-controlled trial (Belch et al., 1985, PMID 4082084) where 12 capsules/day of evening primrose oil for 8 weeks resulted in significantly fewer Raynaud's attacks and improved severity scores versus placebo. GLA stimulates endogenous PGE1 production, promoting vasodilation and inhibiting platelet aggregation. Peer-reviewed reviews and Scleroderma & Raynaud's UK cite GLA (~320 mg/day) as one of few dietary components with documented evidence for Raynaud's.
GLA from evening primrose, borage, or blackcurrant seed oil is supported by a Cochrane review of 7 RCTs for RA, showing reduced pain intensity and improved disability versus placebo. GLA is metabolized to DGLA, which competitively inhibits arachidonic acid pathways and directly suppresses T lymphocytes.
GLA supplementation reduces transepidermal water loss (TEWL) and improves skin hydration and barrier function, which are key determinants of skin aging appearance. Clinical trials in adults with dry skin show statistically significant TEWL improvements with GLA. Anti-inflammatory metabolites of GLA also reduce UV-associated skin damage, indirectly protecting against photoaging.
GLA supports skin elasticity by maintaining barrier function, reducing TEWL, and modulating inflammatory pathways that degrade extracellular matrix proteins including collagen. Experimental evidence shows GLA-containing oils restore UV-reduced collagen content in skin models. Clinical improvements in skin barrier function, hydration, and elasticity are documented in human trials.
Clinical trials have found GLA supplementation can significantly lower plasma triglyceride levels. A 4-month study in 12 hyperlipidemic patients receiving 3 g/day of GLA-enriched linoleic/GLA oil showed a 48% reduction in plasma triglycerides (p<0.001). Two small trials in 31 people also showed GLA lowered triglycerides, LDL, and total cholesterol.
GLA is traditionally used and commercially marketed for depression, including postpartum depression, based on its role in eicosanoid regulation and membrane phospholipid composition important for neurotransmission. However, direct clinical evidence from well-controlled trials is limited, and it is primarily listed as a condition for which GLA is 'used' without strong RCT support.
Gamma-linolenic acid (GLA) is an omega-6 fatty acid found in borage oil, evening primrose oil, and black currant seed oil. It is a precursor to prostaglandin E1, which has hair growth-stimulating properties, and has been used traditionally and in supplement formulations for hair loss. Animal studies and preliminary human data suggest it may reduce androgenetic hair loss.
Gamma-linolenic acid (GLA) is the active omega-6 fatty acid in evening primrose oil proposed to address a GLA deficiency contributing to PMS via prostaglandin E1 deficiency. Clinical RCT evidence via evening primrose oil is mixed to negative in most rigorous trials, though GLA remains widely recommended in complementary medicine for PMS.
Sistemas corporales que minerales traza puede ayudar a apoyar.
Volver